This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refused to receive standard therapy, or for whom no standard therapy is available.
Have spinal cord compression or clinically active central nervous system metastases
Have leptomeningeal disease
Have thromboembolic or clinically significant bleeding events
Have significant cardiovascular disease